Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1947 2
1948 1
1949 1
1950 1
1951 2
1952 2
1953 3
1954 3
1955 4
1956 2
1957 2
1958 1
1959 1
1960 1
1961 2
1962 3
1963 1
1964 1
1965 1
1966 6
1967 5
1968 8
1969 8
1970 3
1971 6
1972 6
1973 9
1974 9
1975 6
1976 7
1977 3
1978 10
1979 5
1980 3
1981 8
1982 12
1983 11
1984 12
1985 9
1986 4
1987 9
1988 6
1989 18
1990 16
1991 15
1992 12
1993 14
1994 17
1995 17
1996 17
1997 12
1998 14
1999 11
2000 4
2001 15
2002 15
2003 13
2004 11
2005 6
2006 15
2007 13
2008 15
2009 14
2010 20
2011 28
2012 16
2013 24
2014 27
2015 32
2016 27
2017 31
2018 36
2019 36
2020 37
2021 28
Text availability
Article attribute
Article type
Publication date

Search Results

767 results
Results by year
Filters applied: . Clear all
Page 1
Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer.
Vykoukal J, Fahrmann JF, Gregg JR, Tang Z, Basourakos S, Irajizad E, Park S, Yang G, Creighton CJ, Fleury A, Mayo J, Paulucci-Holthauzen A, Dennison JB, Murage E, Peterson CB, Davis JW, Kim J, Hanash S, Thompson TC. Vykoukal J, et al. Among authors: davis jw. Nat Commun. 2020 Aug 27;11(1):4279. doi: 10.1038/s41467-020-17645-z. Nat Commun. 2020. PMID: 32855410 Free PMC article.
The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
Eissa A, Elsherbiny A, Coelho RF, Rassweiler J, Davis JW, Porpiglia F, Patel VR, Prandini N, Micali S, Sighinolfi MC, Puliatti S, Rocco B, Bianchi G. Eissa A, et al. Among authors: davis jw. Minerva Urol Nefrol. 2018 Oct;70(5):462-478. doi: 10.23736/S0393-2249.18.03081-3. Epub 2018 Apr 17. Minerva Urol Nefrol. 2018. PMID: 29664244 Free article. Review.
Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.
Visvanathan S, Baum P, Vinisko R, Schmid R, Flack M, Lalovic B, Kleiner O, Fuentes-Duculan J, Garcet S, Davis JW, Grebe KM, Fine JS, Padula SJ, Krueger JG. Visvanathan S, et al. Among authors: davis jw. J Allergy Clin Immunol. 2019 Jun;143(6):2158-2169. doi: 10.1016/j.jaci.2018.11.042. Epub 2018 Dec 20. J Allergy Clin Immunol. 2019. PMID: 30578873 Free article. Clinical Trial.
Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial.
Weiss AR, Chen YL, Scharschmidt TJ, Chi YY, Tian J, Black JO, Davis JL, Fanburg-Smith JC, Zambrano E, Anderson J, Arens R, Binitie O, Choy E, Davis JW, Hayes-Jordan A, Kao SC, Kayton ML, Kessel S, Lim R, Meyer WH, Million L, Okuno SH, Ostrenga A, Parisi MT, Pryma DA, Randall RL, Rosen MA, Schlapkohl M, Shulkin BL, Smith EA, Sorger JI, Terezakis S, Hawkins DS, Spunt SL, Wang D. Weiss AR, et al. Among authors: davis jw. Lancet Oncol. 2020 Aug;21(8):1110-1122. doi: 10.1016/S1470-2045(20)30325-9. Epub 2020 Jul 20. Lancet Oncol. 2020. PMID: 32702309 Clinical Trial.
Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW. Taplin ME, et al. Among authors: davis jw. J Clin Oncol. 2014 Nov 20;32(33):3705-15. doi: 10.1200/JCO.2013.53.4578. Epub 2014 Oct 13. J Clin Oncol. 2014. PMID: 25311217 Free PMC article. Clinical Trial.
Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone.
Efstathiou E, Davis JW, Pisters L, Li W, Wen S, McMullin RP, Gormley M, Ricci D, Titus M, Hoang A, Zurita AJ, Tran N, Peng W, Kheoh T, Molina A, Troncoso P, Logothetis CJ. Efstathiou E, et al. Among authors: davis jw. Eur Urol. 2019 Oct;76(4):418-424. doi: 10.1016/j.eururo.2019.05.010. Epub 2019 Jun 6. Eur Urol. 2019. PMID: 31176622 Free PMC article. Clinical Trial.
The BJUI's clinical trials initiative.
Davis JW, MacLennan G. Davis JW, et al. BJU Int. 2017 Apr;119(4):503. doi: 10.1111/bju.13837. BJU Int. 2017. PMID: 28319352 Free PMC article. Review. No abstract available.
BJUI Compass and open access.
Dasgupta P, Davis JW. Dasgupta P, et al. Among authors: davis jw. BJU Int. 2019 Nov;124(5):713. doi: 10.1111/bju.14911. BJU Int. 2019. PMID: 31646758 No abstract available.
767 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page